A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects

NCT06597422 | Completed Phase 1

• 1 other identifier: STSP-0902-02-001
• Study Type: interventional
• Target: 82
• Locations: 1 country
• Sites: 1

Brief Summary

This trial is a Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of STSP-0902 ophthalmic solution in healthy subjects following single and multiple administrations. The study plans to enroll 80 healthy subjects and is divided into three stages: the single-dose study stage, the multiple-dose study stage, and the tear PK study stage. The single-dose and multiple-dose study stages are randomized, double-blind, placebo-controlled, dose-escalation designs, while the tear PK study stage is a single-dose, open-label design.

Conditions

Neurotrophic Keratitis

Keywords

STSP-0902; Ophthalmic Solution; Healthy Subjects

Outcome Measures

Primary Outcomes (1)

• Incidence of Adverse Events related to study drug

  Number of participants with ocular and systemic adverse events as assessed by CTCAE v5.0.

  Baseline to Day 28

Secondary Outcomes (2)

• STSP-0902 concentration

  Baseline to Day 28

• Incidence of positive detection of anti-STSP-0902 antibodies

  Baseline to Day 28

Study Arms (10)

Single Low Dose Arm

EXPERIMENTAL

Low dose of STSP-0902 ophthalmic solution to study eye. Single dose.

Drug: STSP-0902 ophthalmic solution

Single Middle Dose Arm

EXPERIMENTAL

Middle dose of STSP-0902 ophthalmic solution to study eye. Single dose.

Drug: STSP-0902 ophthalmic solution

Single High Dose Arm

EXPERIMENTAL

High dose of STSP-0902 ophthalmic solution to study eye. Single dose.

Drug: STSP-0902 ophthalmic solution

Single Control Dose Arm

EXPERIMENTAL

STSP-0902 Placebo to study eye. Single dose.

Drug: STSP-0902 Placebo

Multiple Low Dose Arm

EXPERIMENTAL

Low dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.

Drug: STSP-0902 ophthalmic solution

Multiple Middle Dose Arm

EXPERIMENTAL

Middle dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.

Drug: STSP-0902 ophthalmic solution

Multiple High Dose Arm

EXPERIMENTAL

High dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.

Drug: STSP-0902 ophthalmic solution

Multiple Highest Dose Arm

EXPERIMENTAL

Middle dose of STSP-0902 ophthalmic solution to study eye. Six times daily for a total of 8 days.

Drug: STSP-0902 ophthalmic solution

Multiple Control Dose Arm

EXPERIMENTAL

STSP-0902 Placebo to study eye. Multiple doses.

Drug: STSP-0902 Placebo

Tear PK study Arm

EXPERIMENTAL

STSP-0902 ophthalmic solution to both eyes. Single dose.

Drug: STSP-0902 ophthalmic solution

Interventions

STSP-0902 ophthalmic solution DRUG

Eye drop, single dose

Single High Dose Arm; Single Low Dose Arm; Single Middle Dose Arm

STSP-0902 Placebo DRUG

Eye drop, single dose

Single Control Dose Arm

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female subjects aged between 18 and 45 years (inclusive).
• Male subjects with a weight of ≥50.0 kg, and female subjects with a weight of ≥45.0 kg, with a Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive).
• Both eyes have a corrected visual acuity of ≥1.0, with normal or clinically insignificant results from eye examinations, including slit-lamp examination, intraocular pressure measurement, and fundus examination.
• Schirmer I test results for both eyes are ≥10 mm/5 minutes (applicable only to subjects in the tear PK study stage).
• Physical examination, vital signs, 12-lead ECG, chest imaging, and laboratory tests (including hematology, urinalysis, blood chemistry, and coagulation function) are normal or clinically insignificant during the screening period.
• Subjects (including their partners) agree to use effective non-drug contraception during the trial and for 6 months after the last dose and must not plan to conceive, donate sperm, or donate eggs.
• Subjects are fully informed about the content, process, and potential adverse effects of the trial, voluntarily sign the informed consent form, and be willing to complete the trial, follow-up, and related examinations according to the trial plan.

You may not qualify if:

• History or current presence of any eye disease other than refractive errors (e.g., myopia, hyperopia, astigmatism).
• History of any eye surgery (including laser correction surgery) or having only one functional eye.
• Use of any topical eye medication (e.g., artificial tears, traditional Chinese medicine eye drops, antibiotic eye drops, recombinant monoclonal antibody eye drops, eye gels, etc.) within 1 month prior to screening.
• Wearing contact lenses within 2 weeks before screening or needing to wear contact lenses during the clinical study.
• Clinically significant abnormal results from corneal fluorescein staining (applicable only to subjects in the single-dose and multiple-dose study stages).
• History or current presence of any severe systemic disease, including but not limited to cardiovascular, cerebrovascular, respiratory, gastrointestinal, endocrine, metabolic, neurological, hematological, oncological, immune, infectious, or psychiatric disorders, especially those that may affect the eyes (e.g., hypertension, diabetes, hyperthyroidism).
• Abnormal and clinically significant results in any of the following tests: Hepatitis B surface antigen, Hepatitis C antibody, syphilis-specific antibody, or HIV test.
• Allergy to any component of the investigational product or excipients, history of allergies (especially eye allergies), or a known history of food or drug allergies.
• Vaccination within 1 month prior to screening or planned vaccination during the trial.
• Use of prescription drugs, over-the-counter drugs, or herbal medicines within 2 weeks before screening.
• History of treatment with nerve growth factor (NGF) drugs (e.g., murine NGF) or use of other neurotrophic drugs (e.g., B vitamins, fish oil, etc.) within 3 months before screening.
• Underwent any major surgery within 6 months prior to screening or has plans for surgery during the trial.
• History of smoking within 3 months before screening, defined as smoking more than 5 cigarettes or an equivalent amount of tobacco per day on average, or inability to abstain from any tobacco products during the study.
• Regular alcohol consumption within 6 months before screening, defined as an average daily alcohol intake of more than 2 units (1 unit = 360 mL of beer, 45 mL of spirits with 40% alcohol, or 150 mL of wine), or a positive alcohol breath test result, or inability to abstain from any alcohol products during the study.
• Daily consumption of more than 5 cups of coffee or strong tea (each cup ≥150 mL) within 3 months before screening, or inability to abstain during the study.

Sponsors & Collaborators

• Staidson (Beijing) Biopharmaceuticals Co., Ltd: lead

Study Sites (1)

Beijing Tongren Hospital, Capital Medical University

Beijing, Beijing Municipality, 100005, China

Location

Study Officials

• Laichun Lu, Ph.D

  Beijing Tongren Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 9, 2024
• First Posted: September 19, 2024
• Study Start: October 20, 2024
• Primary Completion: January 23, 2025
• Study Completion: January 23, 2025
• Last Updated: April 13, 2026

Record last verified: 2026-04

Locations

CN (1)